In this webinar, Rebecca Fitzgerald of the Hutchison-MRC Research Center at the University of Cambridge, will give a broad overview of the epidemiology and clinical features of esophageal cancer. Focussing on esophageal adenocarcinoma she will discuss the progress that has been made in understanding the molecular landscape of this cancer from whole genome sequencing and RNA sequencing data. She will describe how although the driver gene landscape is highly heterogeneous the mutational signatures and cell signalling pathways converge to indicate the likely cause and vulnerabilities in esophageal adenocarcinoma which pave the way for new therapy approaches.
In the final part of the webinar Rebecca will discuss how earlier detection of relapse and indicators of response to therapy would help to tailor treatment. Blood biopsy to detect circulating tumor DNA is one such approach and Dr. Fitzgerald will present data to show the potential of a ctDNA mutation panel to detect relapse post-surgery in patients with esophageal adenocarcinoma in a retrospective study.